ABBVIE

Abeona Therapeutics resubmits BLA for pz-cel; RiboX Therapeutics receives IND clearance for RXRG001; Nanoscope Therapeutics' MCO-010 improves visual acuity in RP patients; HuidaGene Therapeutics' HG202 receives IND clearance for nAMD; CARsgen's clinical holds removed for BCMA, Claudin18.2, and GPRC5D CAR-T therapies; Lyell Immunopharma acquires ImmPACT Bio, focusing on IMPT-314 and LYL119; EvolveImmune collaborates with AbbVie to develop therapeutic antibodies for cancer.

Top 20 biopharmaceutical companies saw a 2% market cap increase to $4.3trn in Q3 2024, driven by FDA approvals and strategic alliances, despite some declines.

Johns Hopkins scientists identified 16 genes in breast cancer cells that enable survival in the bloodstream post-hypoxia, with MUC1 already in clinical trials. The study, published in Nature Communications, highlights a 'memory' of hypoxic conditions aiding metastasis, particularly in triple-negative breast cancer.

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

Roche to present over 40 abstracts on nine blood disorders at the 66th ASH Annual Meeting, highlighting long-term follow-up data for Polivy®, Lunsumio®, and Columvi®, and new combination data, reinforcing commitment to advancing lymphoma patient outcomes.

Doudna and Charpentier's lawyers seek to revoke their European CRISPR–Cas9 patents after an unfavorable EPO opinion, citing procedural strategy rather than conceding patent invalidity, while maintaining broader patent protection in Europe and the US.

DelveInsight's 'Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024' report details the global pipeline, including clinical trials, therapies, MOA, ROA, and key companies like Pfizer, Incyte Corporation, and AbbVie. It highlights emerging therapies like SDC-1801 and Povorcitinib, recent approvals such as upadacitinib for nr-axSpA, and ongoing Phase III trials like Incyte's povorcitinib for hidradenitis suppurativa.

REGENXBIO Inc. announces participation in UBS Global Healthcare Conference (Nov 13, Rancho Palos Verdes), Stifel 2024 Healthcare Conference (Nov 19, New York), and Piper Sandler 36th Annual Healthcare Conference (Dec 5, New York). Webcasts available at www.regenxbio.com.

Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.

Regeneron's Eylea sales miss estimates, UCB sees potential in Alzheimer's drug bepranemab, Madrigal's Rezdiffra sales exceed expectations, AbbVie partners with EvolveImmune for cancer drugs, Lundbeck acquires Longboard Pharmaceuticals, and PTC Therapeutics awaits FDA decision on Translarna for Duchenne muscular dystrophy.